Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Personalized Desensitization for Donor-Specific Anti-HLA Antibodies in Allogeneic Blood or Marrow Transplantation.

Transplantation and cellular therapy·2025

Same author

Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide.

Transplantation and cellular therapy·2025

Same author

Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation.

Transplantation and cellular therapy·2025

Same author

Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.

Haematologica·2025

Same author

Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma.

Blood advances·2024

Same author

Cost-Effectiveness of Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Bone Marrow Transplantation: Evidence from BMT CTN 1101.

Transplantation and cellular therapy·2023

Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025

Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025

Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025

Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025

Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025

Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 29, 2026

Orthotopic Hind Limb Transplantation in the Mouse

Orthotopic Hind Limb Transplantation in the Mouse

Published on: February 12, 2016

Recent developments in HLA-haploidentical transplantations.

Margaret Showel¹, Ephraim J Fuchs¹

¹Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 289 Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21287, USA.

Best Practice & Research. Clinical Haematology

|November 23, 2015

Summary

This summary is machine-generated.

Hematopoietic stem cell transplants offer cures for blood cancers but donor matching is a barrier. HLA-haploidentical transplants using post-transplantation cyclophosphamide show improved safety and efficacy, expanding treatment options.

Keywords:

Acute myeloid leukemia Cyclophosphamide Graft versus host disease HLA-haploidentical transplantation Matched related donor Matched unrelated donor Mismatched unrelated donor Relapse

More Related Videos

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Mar 29, 2026

Orthotopic Hind Limb Transplantation in the Mouse

Orthotopic Hind Limb Transplantation in the Mouse

Published on: February 12, 2016

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

Area of Science:

Hematology
Transplantation Immunology
Oncology

Background:

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for hematologic malignancies.
Limited availability of matched donors restricts HSCT for many patients.
Historically, HLA-haploidentical HSCT was associated with high rates of graft-versus-host disease and treatment failure.

Purpose of the Study:

To review recent advancements in HLA-haploidentical HSCT.
To highlight the role of post-transplantation cyclophosphamide in improving outcomes.
To discuss the expanding applicability of HSCT for patients lacking matched donors.

Main Methods:

Review of current literature on HLA-haploidentical HSCT.
Analysis of studies utilizing post-transplantation cyclophosphamide.
Discussion of safety and efficacy data from recent clinical trials.

Main Results:

Post-transplantation cyclophosphamide has significantly reduced graft-versus-host disease incidence and mortality.
HLA-haploidentical HSCT with this strategy demonstrates comparable outcomes to matched sibling transplants in select cases.
This approach broadens the donor pool, making HSCT accessible to a larger patient population.

Conclusions:

HLA-haploidentical HSCT, particularly with post-transplantation cyclophosphamide, represents a major breakthrough in transplantation for hematologic malignancies.
This strategy overcomes the critical barrier of matched donor availability.
Further research continues to refine protocols and expand eligibility for this life-saving therapy.